快樂小藥師
// 如果你希望圖片繼續多一點，那就自己再複製增加
- <
- >
目前分類：醫藥知識 (1865)
- Apr 30 Mon 2012 05:45
Horizant - Treatment for Restless Legs Syndrome, United States of America
- Apr 28 Sat 2012 05:41
Vyndaqel (Tafamidis) - Treatment for Transthyretin Familial Amyloid Polyneuropathy
Vyndaqel (tafamidis) is a first-in-class transthyretin stabiliser indicated for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).
- Apr 27 Fri 2012 05:34
Rasagiline - Second-Generation MAO-B Inhibitor
機轉圖也可以參考這邊：
圖解藥理學～22Dopamine pathway
Rasagiline is a second-generation irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease (PD) and the product of a joint development programme between the Danish pharmaceutical company Lundbeck and Teva Pharmaceutical of Israel.
Following successful completion of phase III trials in patients with early and advanced PD, rasagiline was filed for regulatory approval in both the US and Europe in 2003.
- Apr 26 Thu 2012 04:28
Banzel – Treatment for Lennox-Gastaut syndrome
Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures which are associated with Lennox-Gastaut syndrome (LGS) （L~G症候群，雷葛氏症候群） in children and adults.
- Apr 24 Tue 2012 05:33
Trobalt / Potiga – Treatment for Partial-Onset Seizure
Trobalt (ezogabine / retigabine) is indicated for the treatment of partial-onset epileptic seizures in patients aged more than 18 years old. It is being developed and manufactured jointly by Canada-based Valeant Pharmaceuticals and GlaxoSmithKline.
- Apr 23 Mon 2012 05:31
Florbetaben
Alzheimer's disease (AD) is the most common type of dementia, which severely impacts the intellectual abilities of a patient to carry on with their daily lives.
- Apr 22 Sun 2012 05:30
[NEJM][ORIGINAL ARTICLE]Vorapaxar in the Secondary Prevention of Atherothrombotic Events
機轉圖在這邊：
圖解藥理學 20抗凝血機轉10.1
Platelets play a central role in atherothrombosis and are an important target for pharmacotherapy. In patients with acute coronary syndromes, the use of potent platelet inhibitors has been shown to reduce the rate of thrombotic events at the cost of increased bleeding.1-3 In contrast, among patients with stable atherosclerosis, a reduced rate of thrombotic events with antiplatelet therapy in addition to aspirin therapy has not been established.4
- Apr 14 Sat 2012 05:21
[NEJM][REVIEW ARTICLE][CURRENT CONCEPTS]Dengue 登革熱
Cameron P. Simmons, Ph.D., Jeremy J. Farrar, M.D., Ph.D., Nguyen van Vinh Chau, M.D., Ph.D., and Bridget Wills, M.D., D.M.
N Engl J Med 2012; 366:1423-1432
- Mar 25 Sun 2012 04:11
Levitra orodispersible tablet 樂威壯口溶錠 溶解實驗
- Mar 16 Fri 2012 04:53
[藥物試用]3M nexcare skin crack care gel 龜裂修護凝膠試用
之前有跟大家講過很多輕微傷口修復的藥品：
3M 無痛保膚膜（3M Cavilon no sting barrier flim）
流絆 液態絆創膏 Ryuban liquid plaster リュウバン
今天要來介紹另外一個比較不一樣的：
- Mar 14 Wed 2012 07:28
[Clinical infectious Disease]How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?
Abstract
- Mar 12 Mon 2012 04:16
小心！你購買的產品可能中文標示不實
- Mar 07 Wed 2012 04:14
[NEJM][REVIEW ARTICLE]A Patient with Asthma Seeks Medical Advice in 1828, 1928, and 2012
- Mar 03 Sat 2012 10:13
[WebMD]並非每個人都知道保險套的知識
- Feb 28 Tue 2012 05:18
[Epocrates][Journal Watch]Testosterone Supplementation in Older Men: Mixed Messages 老男人要補充睪固酮嗎？
Higher testosterone levels might be associated with better physical performance, but supplementation is recommended only for alleviation of sexual symptoms.
- Feb 19 Sun 2012 07:34
認識近視雷射：何謂PRK、LASEK、LASIK、Epi-LASIK？
使用準分子雷射來矯正屈光不正，可因手術的方式不同主要區分為PRK與 LASIK，各有優缺點。為改善PRK與LASIK的缺點而發展出所謂的LASEK與 Epi-LASIK，相較於PRK與 LASIK仍優劣互見，未有定論。
- Feb 08 Wed 2012 05:07
Cystic fibrosis 囊狀纖維化
- Jan 30 Mon 2012 05:57
[NEJM][CLINICAL THERAPEUTICS]Fingolimod for Multiple Sclerosis
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors' clinical recommendations.
另外有幾篇也建議妳看看：
Laquinimod （Allegro）– new promising treatment of multiple sclerosis
[Medscape]Fingolimod Receives FDA Approval as First Oral MS Treatment
[Medscape][CME]Emerging Therapies in Multiple Sclerosis
- Jan 28 Sat 2012 09:50
[European Heart Journal]Is Aspirin for Primary Prevention of Vascular Events in Low-Risk Women Helpful or Harmful?
Eur Heart J 2011;Nov 16
Study Question:
Do individual patient characteristics identify women who would benefit from aspirin 100 mg every other day for primary prevention of vascular events?
醫藥類 (14)
